Declining incidence of hypoglycaemia in diabetes secondary to chronic pancreatitis: A nationwide cohort study from 2003 to 2022
Authors' conclusion
Hospitalisation for hypoglycaemia in pancreatic diabetes has declined substantially over time, alongside notable changes in treatment patterns.
Study context
- Population
- Adults in Denmark with new-onset diabetes between 1998 and 2022, classified as pancreatic diabetes, type 1 or type 2 diabetes
- Participants
- 583,220 new-onset diabetes
- Exposure
- 2019-2022 vs 2003-2006, within each diabetes subtype
- Pancreatic diabetesn = 3,383
- Type 1 diabetesn = 12,383
- Type 2 diabetesn = 567,454
- Outcome
- Annual incidence of hypoglycaemia leading to hospitalisation
- Follow-up
- 2003-2006 vs 2019-2022
Methodological detailsDanish
- Danish
Main finding
As reported in the abstract
Severe hypoglycaemia incidence, 2019-2022 vs 2003-2006
Incidence rate ratio (95% CI)
Pancreatic diabetes, 2019-2022vs Pancreatic diabetes, 2003-2006declined by 69%
0.33(0.25–0.40)
Type 1 diabetes, 2019-2022vs Type 1 diabetes, 2003-2006declined by 57%
0.43(0.38–0.49)
Type 2 diabetes, 2019-2022vs Type 2 diabetes, 2003-2006declined by 65%
0.35(0.33–0.37)
Observational data: associations, not effects.
Further findings
Metformin use and severe hypoglycaemia
| aHR (95% CI) | ||
|---|---|---|
| Metformin useLower risk | 0.36 (0.26–0.48) | |
| 0.20.5125Adjusted hazard ratio (log scale) |
Treatment trends in pancreatic diabetes
- Decline coincided with a shift from human to analogue insulin and increased metformin use in pancreatic diabetes
Insulin type and hypoglycaemia risk
- All insulin types associated with higher hypoglycaemia risk; insulin analogues lower risk than human insulin
Original publication
Declining incidence of hypoglycaemia in diabetes secondary to chronic pancreatitis: A nationwide cohort study from 2003 to 2022. Diabetes Obes Metab. Published 8 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →